Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs
Deerfield-backed startup Boulevard Bio launches with $65M and a trio of immunology drugs targeting autoimmune cures.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
The brief
Recent coverage from Fierce Biotech, STAT, Endpoints News, Dealroom, BioPharma Dive, MedCity News, FirstWord Pharma, and Yahoo Finance details the launch of the startup Boulevard Bio. Boulevard Bio embarks on a path focused on a trio of immunology drugs, utilizing antibody therapies to pursue targeted autoimmune treatments. Outlets such as BioPharma Dive and Dealroom emphasize the $65 million seed funding secured by the startup. FirstWord Pharma and Endpoints News highlight the company's ambition to make IgAN treatment a quarterly affair, noting its sights on Vera's IgAN drug.
Meanwhile, STAT and MedCity News focus on the involvement of co-founder Schett, characterized as a top autoimmune researcher and immune reset pioneer. Additional coverage from Yahoo Finance points to congratulatory statements from AlivaMab Biologics and Ablexis regarding Boulevard Bio's launch and the ongoing Phase 1 clinical trial of the bispecific antibody BLVD101. This trend emerges as a significant development in the biotechnology landscape, where targeted autoimmune drugs and novel antibody therapies are drawing substantial capital and research attention. The company's strategic alignment with established intellectual property and early-stage clinical work positions it within a competitive field aiming for long-term disease remission.
Coverage does not yet specify detailed timelines for the broader clinical pipeline beyond the ongoing Phase 1 trial for BLVD101. Observers and industry stakeholders will monitor further developments from Boulevard Bio regarding its trio of immunology assets. Future reporting is expected to track the progression of the Phase 1 clinical trial for the bispecific antibody BLVD101 and the advancement of the IgAN treatment program. Coverage does not currently specify subsequent funding milestones or regulatory filing dates for the newly launched startup.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: unsupported claims removed (92% supported) Updated 94d ago.
Quick answers
How much funding did Boulevard Bio launch with?
Boulevard Bio launched with $65 million.
What is the lead asset currently in clinical trials?
The bispecific antibody BLVD101 is currently in a Phase 1 clinical trial.
Who co-founded Boulevard Bio?
Immune reset pioneer Schett co-founded the startup.
Coverage (8)
- AlivaMab Biologics and Ablexis Congratulate Boulevard Bio on its Launch and the Ongoing Phase 1 Clinical Trial of Bispecific Antibody BLVD101 Yahoo Finance · 97d ago
- Newco Boulevard Bio wants to make IgAN treatment a quarterly affair FirstWord Pharma · 97d ago
- Startup Boulevard Bio Launches With Immune Reset Pioneer Schett as Co-Founder MedCity News · 97d ago
- Boulevard starts up with $65M to pursue targeted autoimmune drugs BioPharma Dive · 97d ago
- Boulevard Bio launches with $65M seed to chase autoimmune cures Dealroom · 97d ago
- Boulevard Bio dreams big in immunology with $65M, sights on Vera’s IgAN drug Endpoints News · 97d ago
- Biotech company co-founded by top autoimmune researcher lays out plans with antibody therapies STAT · 97d ago
- Deerfield-backed Boulevard Bio embarks on ‘beautiful path to a cure’ with trio of immunology drugs Fierce Biotech · 97d ago
Topics
Related trends
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
Moderna raises its 2026 outlook and swings to a profit as newer vaccines and cancer treatments gain traction.
Novartis cites cases of previously unknown tumors possibly tied to its SMA gene therapy
Novartis reports cases of tumors in children following treatment with its spinal muscular atrophy gene therapy, Zolgensma.
Revolution Medicines’ pancreatic cancer drug has stunning commercial debut
Revolution Medicines' pancreatic cancer drug Rasonque achieves an eye-popping commercial debut, shattering analyst estimates.
Scientists reverse liver cell aging and cut Alzheimer’s-linked protein in half
Recent reporting highlights scientific breakthroughs targeting cellular aging, liver rejuvenation, and amyloid-beta reduction.